John Caster, MD
Internal Medicine · Springfield, MONPI 1902849854
Payments from drug & device makers
Across 880 payments — averaging $14.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- AstraZeneca$2K
- Lilly USA, LLC$2K
- Boehringer Ingelheim$1K
- Novo Nordisk$1K
- Abbott$784
- plus $4K from 26 others
What the payments were for
- Food & beverage$12,885100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 163 | $2,009 |
| AstraZeneca | 102 | $1,765 |
| Lilly USA, LLC | 115 | $1,695 |
| Boehringer Ingelheim | 100 | $1,394 |
| Novo Nordisk | 63 | $1,021 |
| Abbott | 34 | $784 |
| AbbVie(2 entities) | 64 | $769 |
| Amgen | 40 | $647 |
| Johnson & Johnson | 46 | $543 |
| GSK | 28 | $404 |
| Novartis | 18 | $259 |
| Amarin Pharma, Inc. | 10 | $178 |
| Dexcom, Inc. | 9 | $174 |
| Merck | 11 | $167 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $160 |
| Biohaven Pharmaceuticals, Inc. | 17 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $132 |
| Exact Sciences | 7 | $107 |
| Kowa Pharmaceuticals America, Inc. | 7 | $95 |
| Sanofi | 3 | $65 |
| Eisai Inc. | 4 | $61 |
| Daiichi Sankyo Inc. | 3 | $54 |
| Idorsia Pharmaceuticals US Inc | 3 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $36 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 2 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 2 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$121
- BEVESPI AEROSPHERE$121
- SYMBICORT$121
How this compares
$12,891 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 202 | $165,435 |
| OzempicSemaglutide | 79 | $111,249 |
| JardianceEmpagliflozin | 78 | $64,762 |
| RybelsusSemaglutide | 51 | $57,661 |
| TrulicityDulaglutide | 45 | $48,272 |
| XareltoRivaroxaban | 44 | $47,574 |
| MounjaroTirzepatide | 39 | $43,444 |
| JanuviaSitagliptin Phosphate | 39 | $25,900 |
| TradjentaLinagliptin | 34 | $23,455 |
| FarxigaDapagliflozin Propanediol | 13 | $13,639 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 40 | $11,787 |
| EntrestoSacubitril/Valsartan | 13 | $8,723 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $8,548 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $8,144 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 24 | $7,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $2,009 | $172,731226 claims |
| Novo NordiskOzempic, Rybelsus | $1,021 | $168,910130 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,695 | $91,71684 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,394 | $88,217112 claims |
| Johnson & JohnsonXarelto | $543 | $47,57444 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,765 | $27,74241 claims |
| GSKArexvy, Breo Ellipta, Incruse Ellipta, Shingrix | $404 | $26,93675 claims |
| MerckJanuvia | $167 | $25,90039 claims |
| AbbVieLinzess, Synthroid | $769 | $9,14355 claims |
| NovartisEntresto | $259 | $8,72313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Springfield
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.